

April 4, 2014

As of April 3, Novozymes has purchased an accumulated 1,417,400 shares with a transaction value of DKK 341.7 million under the stock buyback program Novozymes announced in Company announcement No. 17, 2014 and initiated February 17, 2014. Under the program, Novozymes will buy back B shares worth up to DKK 2 billion in total during 2014.

The following transactions have been made under the program in accordance with the provisions of European Commission Regulation (EC) No. 2273/2003 of 22 December 2003, also referred to as the Safe Harbour Regulation:

	Number	Average	Transaction
	of shares	purchase price	value, DKK
Accumulated, last announcement	1,212,400		293,050,864
March 28, 2014	44,000	235.46	10,360,189
March 31, 2014	40,000	237.38	9,495,173
April 1, 2014	41,000	237.62	9,742,395
April 2, 2014	40,000	238.68	9,547,186
April 3, 2014	40,000	237.63	9,505,176
Total accumulated under the program	1,417,400		341,700,983

In addition, transactions necessitated by Novozymes' previously established incentive programs have resulted in a net sale by Novozymes of 2,560 B shares in the period from March 28 to April 3, 2014. The share transactions related to the incentive programs were not part of the Safe Harbour stock buyback program.

Following the transactions stated above, Novozymes owns a total of 5,840,407 treasury shares, corresponding to 1.8% of the stock capital. The total number of shares in the company is 319,700,000, including treasury shares.

Contact information

Investor Relations: Thomas Bomhoff (DK)	+45 3077 1226	tsbm@novozymes.com
Klaus Sindahl (DK)	+45 5363 0134	ksdh@novozymes.com
Martin Riise (USA)	+1 919 649 2565	mrsn@novozymes.com
Press and media:		
Rene Tronborg (DK)	+45 3077 2274	retr@novozymes.com
Frederik Bjoerndal (Europe)	+44 7976138265	tfbh@novozymes.com
Paige Donnelly (USA)	+1 919 218 4501	pagd@novozymes.com
Meng Lian (China)	+86 136 9923 1164	mexl@novozymes.com
Henrique Pellini (Brazil)	+55 41 9288 0282	hqp@novozymes.com
Poonam Kapila (India)	+91 991 082 2339	poka@novozymes.com

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com